Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20022274 | 0.95 | STING1 (1.00) | STING1 | |
| SCHEMBL20716285 | 0.90 | STING1 (0.81) | STING1 | |
| SCHEMBL20022191 | 0.90 | STING1 (0.81) | STING1 | |
| SCHEMBL20049327 | 0.90 | STING1 (0.81) | STING1 | |
| SCHEMBL9208326 | 0.89 | STING1 (1.00) | STING1 | |
| SCHEMBL29362434 | 0.89 | STING1 (1.00) | STING1 | |
| SCHEMBL20022237 | 0.86 | STING1 (0.76) | STING1 | |
| SCHEMBL21437018 | 0.85 | STING1 (0.82) | STING1 | |
| SCHEMBL20049470 | 0.84 | STING1 (0.72) | STING1 | |
| SCHEMBL20022210 | 0.84 | STING1 (0.81) | STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312772-B2 | Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment | MERCK SHARP & DOHME CORP. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11285131-B2 | Benzo[b]thiophene STING agonists for cancer treatment | MERCK SHARP & DOHME CORP. (US) | 2022-03-29 | — | — | US | disclosed |
| CN-110036001-B | Benzo [ b ] thiophene compounds as STING agonists | 默沙东公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20210130466-A1 | Combinations of PD-1 Antagonists and Benzo[b]thiophene STING Agonists for Cancer Treatment | MERCK SHARP & DOHME CORP. (US) | 2021-05-06 | — | — | US | disclosed |
| US-20200330427-A1 | Benzo[b]thiophene STING Agonists for Cancer Treatment | MERCK SHARP & DOHME CORP. (US) | 2020-10-22 | — | — | US | disclosed |
| US-10730849-B2 | Benzo[b]thiophene compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10703738-B2 | Benzo[b]thiophene compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10703738-B2 | Benzo[b]thiophene compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190337917-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
| US-20190337917-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
| US-10414747-B2 | Benzo[b]thiophene compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10414747-B2 | Benzo[b]thiophene compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| WO-2019027858-A1 | BENZO[b]THIOPHENE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2018067423-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-04-12 | — | — | WO | disclosed |
| US-20180093964-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180093964-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130466-A1 | Combinations of PD-1 Antagonists and Benzo[b]thiophene STING Agonists for Cancer Treatment | STING1, MAVS, IRF3 | STING1 1/4885 |
| US-10730849-B2 | Benzo[b]thiophene compounds as STING agonists | STING1, IRF3, CGAS | STING1 1/4885 |
| US-20180093964-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | STING1, IRF3, CGAS | STING1 1/4885 |
| US-10414747-B2 | Benzo[b]thiophene compounds as sting agonists | STING1, IRF3, CGAS | STING1 1/4885 |
| US-11285131-B2 | Benzo[b]thiophene STING agonists for cancer treatment | STING1, IRF3, MAVS | STING1 1/4885 |
| US-11312772-B2 | Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment | STING1, MAVS, IRF3 | STING1 1/4885 |
| US-20190337917-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | STING1, IRF3, CGAS | STING1 1/4885 |
| US-10703738-B2 | Benzo[b]thiophene compounds as STING agonists | STING1, IRF3, CGAS | STING1 1/4885 |
| US-20200330427-A1 | Benzo[b]thiophene STING Agonists for Cancer Treatment | STING1, IRF3, MAVS | STING1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.